119141-88-7
119141-88-7
Chemical Structure
Esomeprazole
Synonym(s): (S)-Omeprazole; (-)-Omeprazole
- CAS No.: 119141-88-7
- Formula:C17H19N3O3S
- Molecular Weight:345.42
IUPAC Name: (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
InChIKey: SUBDBMMJDZJVOS-DEOSSOPVSA-N
SMILES: O=[S@](C1=NC2=CC=C(OC)C=C2N1)CC3=NC=C(C)C(OC)=C3C
Biological Activity: Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Esomeprazole | 99.32% | Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole (Standard) | 99.77% | Esomeprazole (Standard) is the analytical standard of Esomeprazole. This product is intended for research and analytical applications. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole-d3 potassium | Esomeprazole-d3 potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole-d3 | Esomeprazole-d3 is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole-d3 sodium | Esomeprazole-d3 (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. [Content Brief]
- [2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. [Content Brief]
- [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. [Content Brief]
